FDA or­ders In­cyte to hold up yet again in the hunt for block­buster fran­chise

In­cyte $IN­CY will have to wait some­what longer to find out the fate of its pitch to mar­ket rux­oli­tinib cream for the treat­ment of vi­tili­go.

The big biotech an­nounced ear­ly Mon­day that the FDA had had asked for more in­put on the sN­DA, forc­ing reg­u­la­tors to push back their PDU­FA dead­line from April to Ju­ly — a stan­dard 3-month de­lay.

SVB’s An­drew Berens is tak­ing the news in stride. He ob­serves:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER